2026-10-13T11:07:37Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33942001 2026-09-19T09:34:14Z category_7 portal_147 item_type_3 month_year_09_2026

Supplemental Material for: Response to androgen deprivation therapy in a patient with salivary duct carcinoma with an AR W742L mutation: a case report figshare admin karger (2628495) Guan Hui Tricia Lim (25075581) Kenrick Ng (8926150) Martin Forster (3565799) Medicine Medicine <p dir="ltr">Introduction : Currently, there is no standard first line chemotherapy for metastatic salivary ductal carcinoma (SDC), a rare, heterogeneous cancer with high mortality rates. Androgen receptors (AR) have been identified on majority of SDC patients, which makes it a potential therapeutic target using total androgen blockade (TAB), a treatment option already established for prostate cancer. </p><p dir="ltr">Case Presentation: This report explores a case of a patient who developed SDC post-radiotherapy for Hodgkin Lymphoma. He showed partial response to TAB before progression of one of the metastatic lesions. Molecular profiling by Guardant360 demonstrated that he had a mutation AR W742L which has been linked to therapeutic resistance in prostate cancer. The patient subsequently developed leptomeningeal disease which is extremely rare, especially secondary to SDC. </p><p dir="ltr">Conclusion: This study highlights a unique mutation AR W742L which has been associated with castration resistance in prostate cancer but little has been published about it in context of SDC. The case also reiterates the importance of being vigilant for secondary malignancies post-radiotherapy and adds to the growing evidence base for potential clinical benefit of androgen deprivation therapy for SDC. </p> 2026-09-19T09:34:14Z Dataset Dataset 10.6084/m9.figshare.33942001.v1 https://figshare.com/articles/dataset/Supplemental_Material_for_Response_to_androgen_deprivation_therapy_in_a_patient_with_salivary_duct_carcinoma_with_an_AR_W742L_mutation_a_case_report/33942001 CC BY 4.0